{"id":"W3124587416","doi":"10.1200/jco.20.03579","title":"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; St Mary's Hospital Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Internal medicine; Placebo; Lung cancer; Hazard ratio; Population; Oncology; Adverse effect; Cancer; Surgery; Immunotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006839171,0.000373422,0.004099119,0.0002158828,0.0001399494,0.00004510379,0.0002375017,0.0002474746,0.0007764613],"category_scores_gemma":[0.001121601,0.0002140886,0.001128719,0.0003634198,0.0003629474,0.0001792153,0.00005495207,0.001084022,0.000002867684],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006003005,"about_ca_system_score_gemma":0.01445833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001511055,"about_ca_topic_score_gemma":0.001005207,"domain_scores_codex":[0.9932662,0.0007897009,0.004276306,0.0004989075,0.0006899432,0.000478979],"domain_scores_gemma":[0.9909409,0.003058691,0.003793526,0.000371268,0.001394296,0.0004412931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9621119,0.009080695,0.001078086,0.0003530206,0.004631063,0.002866032,0.0006052472,0.0001078879,0.000477246,0.000004636318,0.001391565,0.01729256],"study_design_scores_gemma":[0.9459161,0.03338753,0.0007431922,0.000468176,0.00810885,0.001455139,0.001583481,0.001384349,0.0008365635,0.00001571954,0.005832949,0.0002680118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819226,0.002901673,0.004296495,0.002779508,0.001784015,0.005840981,0.00001542091,0.00001839543,0.0004409068],"genre_scores_gemma":[0.9867811,0.001428221,0.004137315,0.002085766,0.00147054,0.0005364182,0.00001942344,0.00007018265,0.003471003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02430683,"threshold_uncertainty_score":0.9911288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1521484463186084,"score_gpt":0.4832800177848606,"score_spread":0.3311315714662522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}